North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
NCT05489887
Recruiting
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
08/14/2025
Locations: Levine Children's Hospital, Charlotte, North Carolina
Conditions: High-risk Neuroblastoma
Register for Updates
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
NCT05411081
Recruiting
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Duke Cancer Center Cary, Cary, North Carolina
Conditions: Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Congenital Athymia Patient Registry
NCT05329935
Recruiting
This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurr... Read More
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
08/14/2025
Locations: Duke University School of Medicine, Durham, North Carolina
Conditions: Complete DiGeorge Anomaly, Complete DiGeorge Syndrome, Congenital Athymia
Register for Updates
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: The Neurological Institute, PA, Charlotte, North Carolina
Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Register for Updates
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
NCT05316155
Recruiting
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina
Conditions: Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
Register for Updates
Safusidenib Phase 2 Study in IDH1 Mutant Glioma
NCT05303519
Recruiting
This is a 2-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 3 astrocytoma with high-risk features or Grade 4 IDH1-mutant astrocytoma, following standard-of-care radi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4
Register for Updates
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651
Recruiting
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Colorectal Neoplasms
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/14/2025
Locations: University Of NC At Chapel Hill, Chapel Hill, North Carolina
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
NCT05090371
Recruiting
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/14/2025
Locations: University Of NC At Chapel Hill, Chapel Hill, North Carolina
Conditions: Relapsing-Remitting Multiple Sclerosis
Register for Updates
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904
Recruiting
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/14/2025
Locations: Ep0162 50514, Charlotte, North Carolina
Conditions: Stereotypical Prolonged Seizures
Register for Updates
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/14/2025
Locations: University of North Carolina Medical Center, Chapel Hill, North Carolina
Conditions: Colitis, Ulcerative
Register for Updates
SELUTION4BTK Trial
NCT05055297
Recruiting
This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: NC Heart and Vascular Research, LLC, Raleigh, North Carolina
Conditions: Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
Register for Updates